Skip to main content

Table 3 Scenario analyses results

From: Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

Results for high risk patients (aged 65 years and requiring an ICU stay) using all available isolates

Ceftolozane/tazobactam + metronidazole

Piperacillin/tazobactam

Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam

Total costs per patient

$41,838

$42,501

-$662

Total QALYs (discounted) per patient

11.38

11.24

0.14

Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved)

–

–

Dominant

Results for high risk patients (aged 65 years and requiring an ICU stay) using nosocomial isolates

Ceftolozane/tazobactam + metronidazole

Piperacillin/tazobactam

Incremental

Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam

Total costs per patient

$42,979

$44,403

-$1424

Total QALYs (discounted) per patient

11.75

11.53

0.22

Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved)

–

–

Dominant

Results when lifetime health care expenditure for health survivors is excluded

Ceftolozane/tazobactam + metronidazole

Piperacillin/tazobactam

Incremental

Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam

Total costs per patient

$16,286

$17,265

-$978

Total QALYs (discounted) per patient

12.85

12.70

0.15

Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved)

  

Dominant

  1. QALY Quality Adjusted Life Year